Claims for Patent: 9,133,485

Summary for Patent: 9,133,485

Title:	Methods and materials for the reproducible generation of high producer cell lines for recombinant proteins
Abstract:	The invention lies in the field of production of recombinant gene products in eukaryotic cells. The invention refers to methods and materials for the fast and reproducible generation of production cells lines suitable for large scale production of recombinant gene products. The invention encompasses specific vector systems, genetic engineered host-cells and methods of use.
Inventor(s):	Herrmann; Andreas (Allschwil, CH), Abts; Harry (Oberursel, DE), Greulich; Benedikt (Rheine, DE)
Assignee:	Celonic AG (Basel, CH)
Application Number:	12/933,426
Patent Claims:	1. A method for the generation of a high producer host cell for the production of recombinant gene products comprising the following steps: (a) providing a target vector comprising: (i) a first vector portion comprising a reporter gene (RG1) operatively linked to a first expression control sequence comprising a constitutive promoter (P1), (ii) a second vector portion comprising a first selection marker gene (SM1) operatively linked to a second expression control sequence (P2), (iii) a third vector portion comprising a second non-functional selection marker gene (SM2) without operative linkage to an expression control sequence, wherein the first vector portion is located in the 5'-position, the second vector portion is located between the first vector portion and the third vector portion, and the third vector portion is located in the 3'-position, and (iv) a first and a second recognition site for a double-strand break mediating enzyme, wherein the first recognition site is located between the first expression control sequence (P1) and the first reporter gene (RG1) and the second recognition site is located between the second vector portion and the third vector portion, the double-strand break mediating enzyme being a meganuclease or a homing nuclease, and wherein the first and second recognition sites are recognized by the same double-strand break mediating enzyme, (b) introducing the target vector in a host cell under conditions in order to allow random integration of the target vector into the genome of the host cell, (c) selecting a host cell having stably integrated the target vector and showing high transcriptional activity of the reporter gene (RG1), (d) providing an exchange vector comprising: (i) a gene of interest (GOI), and (ii) an inactive second selection marker gene (.DELTA.SM2) operatively linked to a third expression control sequence (P3), wherein the exchange vector comprises a first 5'-homologous sequence and a second 3'-homologous sequence, which allow recombination with sequences of the target vector, (e) introducing the exchange vector into a host cell obtained in step (c) under conditions to allow a double strand break at the first and/or second recognition site as defined in step (a)(iv) and an integration of the exchange vector into the genome of the host cell by double-strand break-mediated homologous recombination, whereby the inactive second selection marker gene (.DELTA.SM2) is activated by an integration of the exchange vector by homologous recombination with the target vector, (f) selecting a high producer cell having integrated the exchange vector by homologous recombination with the integrated target vector, wherein the producer cell expresses the GOI. 2. The method of claim 1, wherein the host cell is a eukaryotic cell. 3. The method of claim 1, wherein the reporter gene (RG1) encodes an enzyme or a luminescent or fluorescent gene product. 4. The method of claim 1, wherein the first expression control sequence (P1) comprises a constitutive promoter. 5. The method of claim 1, wherein the double-strand break mediating enzyme is a meganuclease or a homing nuclease having a recognition site of at least 10. 6. The method of claim 1, wherein a cell is selected having the target vector integrated as a single copy into a single site of the chromosome of the host cell. 7. The method of claim 1, wherein the selecting step (c) is based on a detection of the first selection marker gene (SM1) activity. 8. The method of claim 1, wherein the gene of interest (GOI) lacks a functional expression control sequence. 9. The method of claim 1, wherein the exchange vector comprises the incomplete second selection marker gene (.DELTA.SM2) operatively linked to a third expression control sequence (P3). 10. The method of claim 1, wherein the first 5'-homologous sequence has a length of at least about 1000 nucleotides and/or the second 3'-homologous sequence has a length of at least about 700 nucleotides. 11. The method of claim 1, wherein the exchange vector additionally comprises: a negative selection marker gene. 12. The method of claim 9, wherein the third expression control sequence (P3) is a constitutive promoter. 13. The method of claim 2, wherein the host cell is a mammalian cell. 14. The method of claim 13, wherein the host cell is a CHO cell. 15. The method of claim 4, wherein the constitutive promoter is a CMV promoter. 16. The method of claim 15, wherein the CMV promoter comprises an intron A sequence. 17. The method of claim 1, wherein the double-strand break mediating enzyme is selected from the group consisting of I-SceI, I-SceII, I-Scan, I-SceIV, I-CeuI, I-CreI, I-PpoI, I-TevI, I-TevII, I-TevIll, HO and Endo SceI. 18. The method of claim 5, wherein the double-strand break mediating enzyme is a meganuclease or a homing nuclease having a recognition site of at least 12nucleotides. 19. The method of claim 5 wherein the double-strand break mediating enzyme is a meganuclease or a homing nuclease having a recognition site of at least 18nucleotides. 20. The method of claim 1, wherein the gene of interest (GOI) comprises a partial expression control sequence which is substantially identical to a 3'-portion of the first expression control sequence in the target vector. 21. The method of claim 1, wherein the exchange vector additionally comprises a third selection marker located outside the sequence defined by the first 5'-homologous sequence and second 3'-homologous sequence. 22. The method of claim 21, wherein the third selection marker is a suicide gene. 23. The method of claim 22, wherein the suicide gene is HSV thymidine kinase.

Details for Patent 9,133,485

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2028-03-28
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2028-03-28
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2028-03-28